Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 19, 2026Cancer Research

Abstract LB355: ICP-B794, a B7H3-targeting ADC with a novel linker-payload, demonstrated superior anti-tumor activity and large therapeutic window in preclinical studies

View Full Paper
Ask AI
Bookmark
Share

Authors

DMDongliang MoYGYingxiang GaoXWXiaoyan Wang

Discussion

Loading...

Member takes

Overview

Preclinical studies demonstrate ICP-B794’s efficacy overcoming resistance in NSCLC, suggesting strong therapeutic potential.

Key Points

  • The research investigates the efficacy and safety of ICP-B794, a novel B7H3-targeted antibody-drug conjugate, against solid tumors.
  • Developed ICP-B794 with a novel linker-payload.
  • Evaluated anti-tumor efficacy in NCI-H1155 NSCLC xenograft model.
  • Assessed safety and pharmacokinetics in GLP toxicology study in monkeys.
  • Compared ICP-B794 with other B7H3-ADCs based on different linker-payload platforms.
  • ICP-B794 achieved complete tumor regression at a lower dose than DS-7300.
  • Demonstrated a 267-fold safety window compared to DS-7300.
  • Exhibited high potency in in vitro assays and favorable pharmacokinetic profile.

Cite This Study

Mo et al. (2026) studied this question.

synapsesocial.com/papers/69e473ff010ef96374d8fbc5https://doi.org/10.1158/1538-7445.am2026-lb355
View Full Paper
Ask AI
Bookmark
Share